Cell and Gene Therapy Manufacturing Services Market

Aug 2023| BIO245A| BCC Publishing

Report Highlights

The global cell and gene therapy manufacturing services market reached $4.9 billion in 2022, should reach $5.7 billion by 2023 and $11.8 billion by 2028 with a compound annual growth rate (CAGR) of 15.7% during the forecast period of 2023-2028.

Report Includes

  • 34 data tables and 18 additional tables
  • An overview of the global cell and gene therapy manufacturing services market
  • Analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
  • Highlights of the market potential and quantification of market based on therapy type, application, disease, and end-user
  • A look into current technologies underlying the market as well as the effects new technologies will have on the market
  • Coverage of clinical trials pipeline, partnership between pharmaceutical companies, and Contract Development & Manufacturing Organization (CDMO)
  • Insights into investments from multiple stakeholders, and discussion on increasing focus on personalized medicine for rare and chronic conditions
  • Information on recent mergers, acquisitions, collaborations, agreements, product launches, and expansions in the market and a relevant patent analysis
  • Company profiles of major players within the industry, including Catalent, Charles River Laboratories, Lonza, Merck KGaA, and Thermo Fisher Scientific

Report Scope

The scope of this study encompasses an investigation of cell and gene therapy manufacturing services. BCC Research analyzes the manufacturing services based on therapy type, application, disease, and end user. BCC determines the current market status in each segment, examines its impact on future markets, and presents growth forecasts over the next six years. The recent report provides a detailed analysis of the market's drivers, challenges, and opportunities. The report also covers market projections to 2028 and market share for key market players. The report includes the company profiles of the key players with detailed information about their business segments, financials, product portfolios, and recent developments. The report also provides the ESG perspective, emerging technologies, and investment outlook.

Frequently Asked Questions (FAQs)

The cell and gene therapy manufacturing services market are estimated to be $4.9 billion in 2022 and is forecasted to grow at a CAGR of 15.7% to reach a value of $11.8 billion in 2028.
The key factors contributing to the growth of the market include increasing investments, capacity expansions for clinical and commercial manufacturing, increasing prevalence of chronic diseases, and increased healthcare expenditure are driving the cell and gene therapy manufacturing services market.
In this report, the market is segmented based on type, application, disease, end-user, and region.
Clinical Manufacturing segment will dominate the market by the end of 2028.
Major players in the market are Lonza, FUJIFILM Diosynth, Charles River, Thermo Fisher and Merck KGaA.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.

Report Synopsis

Report Metrics Details
Base year considered 2022
Forecast period considered 2023-2028
Base year market size $4.9 billion
Market size forecast $11.8 billion
Growth rate CAGR of 15.7% for the forecast period of 2023-2028
Units considered $ Millions
Segments covered Type, Application, Disease, End User
Regions covered North America, Europe, Asia-Pacific, Rest of the World (RoW)
Countries covered U.S., Canada, U.K., Germany, France, Rest of Europe, China, Japan, Australia, Rest of APAC
Key Market Drivers
  • Increasing Investment and Funding for CGT Development
  • Capacity Expansions for Clinical and Commercial Manufacturing
  • Rising Prevalence of Chronic Diseases and Focus on Rare Diseases
  • Increasing Strategic Collaborations and Acquisitions
Companies studied

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: Cell and Gene Therapy Manufacturing Services Market138Free
Chapter- 1: Introduction5Free
Chapter- 2: Summary and Highlights4Free
Chapter- 3: Market Overview and Technology Background9Free
Chapter- 4: Market Dynamics9Free
Chapter- 5: Emerging Technologies5Free
Chapter- 6: Market Breakdown by Type18Free
Chapter- 7: Market Breakdown by Application 6Free
Chapter- 8: Market Breakdown by Disease8Free
Chapter- 9: Market Breakdown by End User7Free
Chapter- 10: Market Breakdown by Region18Free
Chapter- 11: Sustainability: An ESG Perspective7Free
Chapter- 12: M&A, Funding Outlook and Competitive Landscape 7Free
Chapter- 13: Company Profiles35Free
Cell and Gene Therapy Manufacturing Services Market

Single User License: $5500

Become a Member

Already a member? Login to access this report free.

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
Custom Research

Need a custom data table, graph or complete report? Tell us more.